Q-omics provides the consensus-scored PRDM9 profile across patient tissues and cancer cell-line models. PRDM9 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRDM9 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, PRDM9 RNA expression shows 6,468 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, HNSC, and STAD as cancer lineages where PRDM9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDM9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDM9 survival associations across molecular data types. PRDM9 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDM9 RNA expression–survival associations across cancer types. High PRDM9 expression shows unfavorable associations in KIRC, LUAD, KICH, COAD and THYM, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRDM9 RNA expression.
This table summarizes PRDM9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PRDM9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDM9 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, LUAD and UCEC. The HNSC box plot shows higher PRDM9 RNA expression in tumor versus normal tissue (log2 FC = +0.054, t-test p = .002).
This table shows molecular features associated with PRDM9 in patient tissues and cancer cell lines. In patient samples, PRDM9 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PRDM9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
